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Transcription regulationThe transcriptional regulation of the Mrf4/Myf5 locus depends on a multitude of enhancers that, in equilibria
with transcription balancing sequences and the promoters, regulate the expression of the two genes
throughout embryonic development and in the adult. Transcription in a particular set of muscle progenitors
can be driven by the combined outputs of several enhancers that are not able to recapitulate the entire
expression pattern in isolation, or by the action of a single enhancer the activity of which in isolation is
equivalent to that within the context of the locus. We identiﬁed a new enhancer element of this second class,
ECR111, which is highly conserved in all vertebrate species and is necessary and sufﬁcient to drive Myf5
expression in ventro-caudal and ventro-rostral somitic compartments in the mouse embryo. EMSA analyses
and data obtained from binding-site mutations in transgenic embryos show that a binding site for a TEA
Domain (TEAD) transcription factor is essential for the function of this new enhancer, while ChIP assays show
that at least two members of the family of transcription factors bind to it in vivo.l).
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The four myogenic regulatory factors (MRFs), Myf5, Mrf4, MyoD
and Myogenin, members of the basic helix–loop–helix (bHLH)
superfamily of transcription factors, play a key role in vertebrate
skeletal myogenesis. In the mouse Myf5 is the ﬁrst MRF to be
expressed and it is considered to be a skeletal muscle determination
gene. It has been shown that in some muscle precursors Mrf4 and
MyoD also behave as determination factors (Kablar et al., 1999; Kablar
et al., 2000; Kassar-Duchossoy et al., 2004; Tajbakhsh et al., 1996) and
they, together with Myf5, have chromatin remodelling properties
(Bergstrom and Tapscott, 2001; Gerber et al., 1997).
In the mouse,Myf5 is ﬁrst detected around 8.0 days post-coitum
(dpc) in the dermomyotomal dorso-medial lip and by 9.5 dpc it
appears in the ventro-lateral lip, the myotome, and the branchial
arches (Ott et al., 1991; Summerbell et al., 2000). By 10.5 dpc Myf5
is also expressed in the developing limbs and the myoblasts
migrating through the hypoglossal cord. Its expression is thenmaintained in all skeletal muscle precursors until it is down-
regulated at late gestation stages. In the adult, Myf5 is only
expressed in satellite cells and muscle spindles (Zammit et al.,
2004). Mrf4 expression is biphasic. The embryonic phase starts at
9.0 dpc with expression detected in differentiated myocytes
located in the central portion of the myotome of rostral somites.
By 9.5 dpc (24–28 somites), Mrf4 expression is activated in
undifferentiated cells of the ventral somitic compartment, coin-
ciding with or closely preceding Myf5 expression at this location
(Summerbell et al., 2002). By 10.5 dpc, Mrf4 expression extends
throughout the myotome but is absent from muscle progenitors of
the branchial arches and the limbs. Mrf4 expression is then
downregulated in a rostrocaudal direction before the onset of the
foetal phase of expression which is initiated in the limbs, followed
by an upregulation of Mrf4 expression in all skeletal muscles
(Carvajal et al., 2001).
The genetic networks that control myogenesis have been shown to
vary depending on the mesoderm of origin of the particular
progenitor. Thus myogenesis of trunk precursors, that originate
from segmented mesoderm, requires Pax3 (Tajbakhsh et al., 1997;
Bajard et al., 2006; Brunelli et al., 2007) and is induced by Wnt
signalling (Anakwe et al., 2003; Abu-Elmagd et al., 2010; Galli et al.,
2004; Geetha-Loganathan et al., 2005; Munsterberg et al., 1995),
while the expansion of muscle progenitors in the myotome has been
shown to be modulated by Notch and Myostatin signalling interfering
with terminal differentiation (Manceau et al., 2008; Schuster-Gossler
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that originate from migratory mesodermal populations that transit
the branchial arches requires Tbx1 (Sambasivan et al., 2009) and is
inhibited by Wnt signalling (Tzahor et al., 2003). Myogenesis in facial
muscle precursors that give rise to extraocular muscles, which
originate from unsegmented pre-chordal mesoderm, requires Pitx2
(Dastjerdi et al., 2007; Dong et al., 2006; Shih et al., 2007) while other
facial muscles of splachnic mesodermal origin require Isl-1 (Nathan et
al., 2008).
The requirement for a particular signalling environment or
transcription factor in myogenesis is thus linked to the activation of
survival or proliferative gene networks in progenitor cells and/or the
activation of the MRFs which trigger differentiation. In this paper we
show that a TEA Domain (TEAD) binding site is required for the
activation of Myf5 expression in a very precise subdomain within the
ventral somite, further subdividing the already complex signalling
environment of trunk muscle precursors. Finally we also show that at
least two members of the TEAD family of transcription factors are
bound in vivo to the enhancer, our interpretation being that this
binding occurs through the essential TEAD binding site.Materials and methods
Comparative analysis of genomic sequences
The genomic sequences for nine species (about 300 kb upstream
and 50 kb downstream of the Myf5 promoter) were analysed using
the mVISTA bioinformatic tool (http://genome.lbl.gov/vista) and
aligned with MLAGAN. The conservation parameters were set as
follows [common name; species (% of conservation identity; minimum
conservation window)]: human, Homo sapiens (70%, 100 bp); rhesus
monkey,Macaca mulata (70%, 100 bp); cow, Bos taurus (70%, 100 bp);
opossum,Monodelphis domestica (60%, 100 bp); chicken, Gallus gallus
(55%, 100 bp); frog, Xenopus tropicalis (50%, 100 bp); medaka, Oryzias
latipes (45%, 100 bp); zebraﬁsh, Danio rerio (45%, 100 bp).Preparation of plasmid constructs
ECR111 was ampliﬁed by PCR from total mouse genomic DNA
using the oligonucleotides: ECR111-F (5′ TTC AGG CTT GGG GGG AAG
TC 3′) and ECR111-R (5′ CAA AAT AAC CAT TAG GAA TGC 3′). The
Brain Enhancer (BE), as described by Daubas et al. (2009), was
ampliﬁed using the oligonucleotides BE-F (5′ TCT AAG ATG AAC AGC
AGC CTG A 3′) and BE-R (5′ TGG CTA CTC ATG AGA CTA TTT CA 3′). All
PCR fragments were subcloned into the pCR2.1-TOPO vector (Invitro-
gen) and sequenced. We used a modiﬁed version of plasmid pEEBZ
(Teboul et al., 2002) containing only the Myf5 minimal promoter
(Summerbell et al., 2000), a nlacZ reporter gene and a single cloning
site upstream, to subclone the different enhancer elements. Full
information on all cloning steps can be obtained on request.Homologous recombination in Escherichia coli
We generated a deletion cassette using the following oligonucle-
otides for the 5′ homology arm: 5HA-F, 5′ TCT AAA TTA TAT TGC ACA
GAG TTC 3′ and 5HA-R, 5′ GAA CCA CCT TAA GAA CCA ATA C 3′; for the
3′ homology arm: 3HA-F 5′ tgg ttc tta agg tgg ttc TTT TCT TTT TAT GTG
ACT ACA GTA A 3′ and 3HA-R, 5′ ATA TAA AAT GTG GAA AGA TCA GTC
3′. The lowercase in the 3HA-F oligonucleotide is complementary to
the 5HA-R. After ampliﬁcation individual homology arms were joined
by PCR to generate the deletion cassette.
The cassette was then used to delete ECR111 from the BAC
construct B195APZ (Carvajal et al., 2001) to generate B195APZΔ111 by
linear recombination as previously described (Carvajal et al., 2008).Production of transgenic mice and whole-mount histochemistry
All in vivo experimentation was performed according to United
Kingdom Home Ofﬁce Regulations. BAC DNA was prepared using the
QIAgen Maxiprep Kit (Qiagen) following our own modiﬁcation of the
protocol (Carvajal et al., 2001) and used to inject fertilisedmouse eggs
from CBA/Ca×C57Bl/6 crosses, as previously described (Yee and
Rigby, 1993). Embryos were sectioned using a vibrotome at 70 μm
following agarose embedding or using a cryostat at 10 μm following
LAMB/OCT (Thermo Fisher Scientiﬁc) embedding following manufac-
turer's instructions. The protocols for ß-Galactosidase and Alkaline
Phosphatase staining of mouse embryos have also been described
elsewhere (Carvajal et al., 2001).
Immunohistochemistry
For whole-mount immunohistochemistry, embryos were dehy-
drated through a methanol series (50% to 100% MeOH), ﬁxed
overnight in a 4:1 solution of MeOH and DMSO, incubated in a 4:1:1
solution of MeOH, DMSO, 30% (v/v) H2O2 for 4 h and rehydrated
through a MeOH/PBT [PBS+0.5% (v/v) triton X-100] series (50% to
15% MeOH). For immunostaining, embryos were incubated in PBTBG
[PBT, 2% (v/w) BSA, 10% (v/v) goat serum] for 4 h. Individual TEAD
antibodies (see below) were added (1:100–1:250 dilutions), embryos
were incubated overnight at 4 °C, washed in PBT overnight at 4 °C and
equilibrated in PBTBG. Fluorescent conjugated antibody (Alexa Fluor
488 goat anti-mouse IgG; 1:1000) was added and embryos were
incubated overnight at 4 °C. Prior to visualisation, embryos were
washed in PBT and transferred to 50% (v/v) glycerol.
For immunohistochemistry on sections, embryos were ﬁxed
overnight in 4% (w/v) PFA, embedded and sectioned. Sections were
washed in PBT and incubated in PBTBG for 1 h. Individual TEAD
antibodies (see below) were added (1:100–1:500 dilutions), incu-
bated for 1 h at room temperature, followed by an overnight
incubation at 4 °C and equilibrated in PBTBG. Fluorescent conjugated
antibody (Alexa Fluor 488 goat anti-mouse IgG; 1:1000 or Alexa Fluor
488 goat anti-rabbit IgG; 1:1000) was added and sections incubated
for 1 h at room temperature. Prior to visualisation, sections were
washed in PBT.
Electrophoretic mobility shift assays (EMSAs) and supershifts
EMSA experiments were performed as previously described
(Gilthorpe et al., 2002). Whole-cell protein extracts were prepared
from isolated trunks of 10.5 dpcmouse embryos. Speciﬁc competitors
were added at 10- or 50-fold molar excess. For supershift experi-
ments, anti-TEAD1 antibody was added to the reaction 15 min before
the addition of the biotin-labelled probe. Full oligonucleotide
sequences can be supplied upon request.
Protein in vitro translation (IVT) and Western blotting
cDNAs for the four members of the TEAD family were cloned in the
pcDNA3.1(−) vector and proteins synthesised in vitro using the TNT®
Coupled Reticulocyte Lysate System (Promega) following manufac-
turer's instructions. At least two transcript variants exist for TEAD4
and we cloned the sequences equivalent to NCBI accession numbers
NM_011567 (variant 1) and NM_001080979 (variant 2) and
performed IVT on both together. IVT proteins were separated through
a 10% SDS-PAGE gel, electro-blotted and blocked in 5% (w/v) dry milk.
Primary and secondary antibody incubations were performed in 5%
(w/v) dry milk. The antibodies used were as follows: mouse anti-
TEAD1 (Aviva Systems Biology, ARP39521, 1: 2000; BD Biosciences,
610922, 1:1000); rabbit anti-TEAD2 (Santa Cruz Biotechnology, sc-
67115, 1: 2000); rabbit anti-TEAD3 (Aviva Systems Biology,
ARP33429, 1:1000); mouse anti-TEAD4 (Aviva Systems Biology,
Fig. 1. The ECR111 enhancer drives a highly dynamic somitic pattern. (A) Graphical
representation of the location of ECR111 in relation to theMrf4 andMyf5 genes and the
output of the VISTA analysis of the −112.1 kb to −110.5 kb interval in the upstream
region of the Mrf4/Myf5 locus generated by comparing the mouse sequence (base
genome) to that of 8 different vertebrate species. The red peaks represent conserved
non-coding sequences that deﬁne the ECR111 enhancer. The position in relation to the
transcription initiation site for Myf5 is given (in kb) above the graph; numbers on the
right indicate the percentage of conservation. (B, E, and H) Transgenic embryos carrying
the ECR111-MZ construct and details of the cervical (C, F, and I) and thoracic (D, G, and
J) aspects of the expression. (B−D) At 26 somite stage, the enhancer drives expression
in the ventral half of cervical somites and at the base of limb-level somites. (E−G) At 30
somite stage there is an expansion of the domain of expression in cervical somites and
an upregulation of transgene expression in thoracic somites; around half of interlimb
somites express the transgene. Note the clear localisation of expression particularly at
the caudal region, and the expression spanning the width of the somite at more ventral
positions of cervical and thoracic somites. (H−J) By 34 somite stage, all thoracic
somites express the transgene in caudal and rostral somitic regions, although
expression extends more dorsally at the caudal domain. Red boxes in B, E and H
indicate the close up regions shown in the remaining panels.
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goat anti-rabbit IgG (H+L)-HRP (BioRad; 1:2000) and goat anti-
mouse IgG (H+L)-HRP (BioRad; 1:2000). Conjugated HRP was
detected using the Amersham ECL plus Western Blotting Detection
System (GE Healthcare).
Chromatin immunoprecipitation (ChIP)
Trunks from 10.5 dpc embryos were cross-linked in 1% (v/v)
formaldehyde at 4 °C for 20 min, the reaction was quenched with
125 mM glycine, and the embryos were homogenised and sonicated
to give chromatin of 200–1000 bp. Chromatin was incubated
overnight at 4 °C with a TEAD antibody or isotype controls (Mouse
IgG: AbCam, Rabbit IgG: Santa Cruz Biotechnology) prebound to
Protein G magnetic dynabeads (Invitrogen). Cross-linking was
reversed by an overnight incubation in Elution Buffer [100 mM
NaHCO3, 1% (w/v) SDS] at 65 °C, DNA puriﬁed using the QIAquick PCR
puriﬁcation kit (Qiagen) and ampliﬁed using the oligonucleotides:
ChIP111-F: 5′ TTC AGG CTT GGG GGG AAG TC 3′, ChIP111-R: 5′ CAA
AAT AAC CAT TAG GAA TGC 3′, ChIP-control-F: 5′ AAG TCC ACT ACC
ATG GAT CGG 3′ and ChIP-control-R: 5′ GTC AGA GCA GTT GGA GGT
GG 3′.
Results
Isolation of an enhancer that drives expression in ventro-caudal and
ventro-rostral somitic compartments
We have previously shown that the region located between
−140 kb and−88 kb upstream of theMyf5 transcriptional start site is
required for the expression of both Mrf4 and Myf5 in ventral somitic
compartments (Carvajal et al., 2001). Sequence conservation analysis
using the VISTA bioinformatic tools (Dubchak and Ryaboy, 2006)
identiﬁes at least four evolutionarily conserved regions (ECRs) in this
interval, one of which (ECR111, 527 bp, which corresponds to the E3
putative enhancer described by Maak et al., 2006), is located 111 kb
upstream of Myf5 and is conserved throughout vertebrate evolution
being present in mammals, birds, amphibians and ﬁsh (Fig. 1A). As
ECR111 is the most conserved sequence in the Mrf4/Myf5 locus, we
decided to concentrate ﬁrst on the transgenic analysis of this putative
enhancer. We cloned ECR111 upstream of theMyf5minimal promoter
(Summerbell et al., 2000) and a nLacZ reporter gene (construct
ECR111-MZ) and analysed the expression pattern driven by it in
transgenic animals (n=5, including 2 stable lines). At 9.25 dpc (23–
24 somites), ECR111 drives expression in a few isolated cells in the
cervical somites (Fig. S1A). The pattern driven by the transgene
evolves rapidly and by 9.5 dpc (26 somites) expression is clearly
observed in cervical somites and isolated cells at ventral positions in
limb-level somites (Figs. 1B–D). By early 10.0 dpc (30 somites), there
is a general upregulation of the cervical somitic expression and a
rostro-caudal expansion of the thoracic domain, which follow the
same pattern as the cervical somites and thus expression is mainly
observed in the ventral half of somites predominantly in the caudal
and rostral edges (Figs. 1E–G). By 10.5 dpc (34 somites) cervical
somitic expression is maintained, or slightly reduced, while all
thoracic somites express the transgene in rostral and caudal edges,
including some expression in the ventral half of the myotome (Figs.
1H–J). From 11.5 dpc expression is downregulated so that by 12.5 dpc
transgene activity can only be faintly detected in some shoulder and
intercostal muscles (Fig. S1B) and is absent from 13.5 dpc onwards.
Within the somite, expression is observed in both the dermomyo-
tomal and myotomal compartments, depending on the dorso-ventral
level (Fig. 2). At more dorsal levels expression is restricted to
myotomal myonuclei located in rostral and caudal positions, although
nuclei located in the caudal part of the myotome are more prevalent
(Fig. 2B). At more ventral somitic levels, expression is observed both
Fig. 2. The ECR111 enhancer drives expression in the myotome and in the
dermomyotome. (A) Transgenic embryo carrying the ECR111-MZ and transverse
(B, C) or saggital (D) sections of the same embryo. (B) At more dorsal positions,
expression is restricted to the myotome, particularly the caudal regions, while (C) at
more ventral positions expression is observed in both the myotome (white
arrowheads) and the dermomyotome (black arrowheads), again preferentially in the
caudal somitic region. (D) Saggital section through an interlimb somite shows that the
expression is mainly restricted to the myotomal compartment, with some cells
expressing the transgene in the dermomyotome as shown in the close-up inset (D′). C:
caudal; R: rostral; m: myotome; dm: dermomyotome. The position and orientation of
the sections are shown as red lines in A. The somites are numbered according to their
rostro-caudal position so that the most rostral is somite 1.
375R. Ribas et al. / Developmental Biology 355 (2011) 372–380in the myotome and in the dermomyotome (Fig. 2C, white and black
arrowheads, respectively) in rostral and caudal positions. Once again,
most of the nuclei expressing the transgene are located caudally
within the somite, both in the myotome and in the dermomyotome.
Transverse sections (Fig. 2D) conﬁrm this observation, as the
transgene drives expression in the ventral half of the myotome and
only in the ventral quarter of the dermomyotome.
ECR111 is necessary for Myf5 ventral somitic expression, but not for
Mrf4 expression
Having shown that ECR111 is sufﬁcient to drive expression in the
ventral half of the somite, we deleted this sequence from BAC clone
B195APZ, which we have previously shown to be able to drive the
entire expression patterns of bothMrf4 andMyf5 in the embryo and in
the adult (Carvajal et al., 2001; Zammit et al., 2004), and generated
construct B195APZΔ111. This BAC contains human placental alkaline
phosphatase (AP) and nlacZ (Z) as reporter genes for Mrf4 and Myf5,
respectively, and allows for the analysis of the effect of a single
deletion on the expression of the two linked genes in transgenic mice
(n=2 stable lines). At around 9.5 dpc (24–26 somites), the transgene
fails to driveMyf5–nlacZ expression in the ventral half of cervical and
thoracic somites (data not shown), while there are no changes in the
expression pattern of Mrf4–AP (Fig. S2A) compared to embryos
carrying the wild type B195APZ BAC clone (Fig. S2B). By 10.5 dpc,
Myf5–nlacZ expression in absent from the ventral half of themyotome
in thoracic and cervical somites and the ventral quarter of the
dermomyotome (Figs. 3B, F, and J, Fig. S2C), although clear expression
can be observed in the ventral somitic bud (Fig. S2D), while Mrf4–AP
expression is identical to that driven by the wild type construct
(Fig. 3). Therefore, at these stages the expression pattern driven by
ECR111 seems to be complementary to that driven by B195APZΔ111,
and the sum of both patterns could result in the recapitulation of the
entire expression pattern ofMyf5. Interestingly, this does not occur at
later stages (Fig. S2E and F) and thus neither the B195APZΔ111 or the
ECR111-MZ transgenes drive Myf5–nlacZ expression in the ventral
half of tail somites, indicating that this aspect of the expression, whilebeing dependent on ECR111, cannot be driven by the enhancer in
isolation.
ECR111 contains a TEAD binding site necessary for enhancer activity
In order to reﬁne the essential sequences for enhancer function,
we proceeded to identify putative binding sites within ECR111 by
electrophoretic mobility shift assays (EMSAs) using 34 bp overlapping
oligonucleotides designed to span the most conserved regions within
ECR111. Protein extracts were obtained from the trunk region of
10.5 dpc wild type (C57Bl6/CBA) embryos. Of the 26 double stranded
oligonucleotides tested, 10 generated a distinct shift in this assay and
we performed competition analyses using unlabelled oligonucleotides
which show that these correspond to 6 independent binding sites
(data not shown). These sites were named according to their position
within the enhancer as BS-1 to BS-6.
The shift generated by oligo#2 (BS-1) was completely abolished by
cold oligo#1 (data not shown) and thus the binding sitewas reﬁned to
the 17 bp interval deﬁned by the overlap of these two oligonucleo-
tides. Within this interval, there is a highly conserved canonical M-
CAT binding site (Mar and Ordahl, 1990), known to be involved in the
regulation of muscle-speciﬁc genes and recognised and bound by
members of the TEAD family of transcription factors (Farrance et al.,
1992). A cold oligonucleotide derived from the chicken troponin-T
gene and containing a consensus binding site (Pasquet et al., 2006)
efﬁciently abolishes the shift generated by oligo#2, while an
oligonucleotide in which the binding site has been mutated
(CATTCCTNggTaCCT; oligo#2-m1) is unable to compete with wild
type oligo#2, even at high molar excesses (Fig. S3A). Finally, a TEAD-1
antibody that binds to three members of the TEAD family (see below)
recognises the protein (or protein complex) binding in our assay and
generates a supershift (Fig. S3A). These data indicate that, at least in
EMSA assays, a member of the TEAD family of transcription factors is
able to bind to the 17 bp sequence deﬁned by the overlap between
oligo#1 and oligo#2. Oligo#25 (BS-6) also contains a M-CAT binding
site but this was not efﬁciently competed with the chicken troponin-T
oligonucleotide or oligo#25 mutated at the M-CAT binding site.
Intriguingly, the band-shift was abolished by the anti-TEAD1 antibody
(Fig. S3B). The remaining shifting oligonucleotides did not contain any
obvious muscle-related binding sites and thus were further analysed
by competition with overlapping oligonucleotides and with oligonu-
cleotides mutated at three consecutive nucleotides in order to
determine the sequence required for binding. In this way we
predicted YY1 binding sites in oligo#7 (BS-2) and oligo#15 (BS-4),
an AP-1/CBP/NF-Y binding site in oligo#9 (BS-3), and an AP-1/NF-E
binding site in oligo#18 (BS-5). The location and sequences of the
mutations, as well as the predicted protein binding sites, can be found
in Fig. S4.
We then introduced the mutations shown to abolish binding in
EMSA assays into our ECR111-reporter plasmid construct in order to
assess the requirement for these binding sites in the pattern driven by
ECR111. The combined mutation of binding sites BS-4, BS-5 and BS-6
(construct ECR111[m456]-MZ) does not affect the expression pattern
driven by ECR111 (Fig. 4A; n=4), while we could not detect
expression in any of the transgenic embryos carrying the construct
ECR111[m123]-MZ, in which BS-1, BS-2 and BS-3 had been mutated
(data not shown). In order to distinguish between lack of expression
due to the introduced mutation or due to silencing at the integration
site, we generated a new base construct which also carries the Myf5
brain element (Daubas et al., 2009) as an internal control (construct
ECR111-BE-MZ). This new construct is thus able to drive both somitic
and brain expression (Fig. 4B). Mutation of BS-1 (M-CAT), BS-2 (YY1)
and BS-3 (AP-1/CBP/NF-Y) (construct ECR111[m123]-BE-MZ) abol-
ishes the function of ECR111 at 10.5 dpc as the construct is not able to
drive somitic expression, while brain expression is maintained,
indicating that the lack of expression is due to the mutations
Fig. 3. Deletion of ECR111 abolishes Myf5 expression in caudal and rostral somitic regions. 10.5 dpc embryos from transgenic lines carrying the B195APZ wild type (A and C) or
B195APZΔ111 (B and D) BAC constructs, and details of the expression patterns in cervical (E−H) and thoracic (I−L) somites. (B) Deletion of ECR111 from the BAC shows that this
enhancer is necessary for Myf5 expression in the caudal and rostral regions in cervical (F) and thoracic (J) somites, while expression in the somitic bud (J, arrowheads) and Mrf4
expression are not changed in the absence of the enhancer (D, H, and L) when compared to the pattern driven by B195APZ (C, G, and K). Note the domain of expression that spans the
ventral half of the somite in embryos carrying the wild type BAC construct (arrowheads in E and I).
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isolation (construct ECR111[m1]-BE-MZ) is sufﬁcient to abolish
ECR111 function, while not affecting the brain expression driven byFig. 4. Transgenic mutation analysis shows that BS-1 is essential for enhancer function.
(A) Mutation of the putative BS-4, BS-5 and BS-6 binding sites (construct ECR111
[m456]-MZ) does not interfere with ECR111 activity at 10.5 dpc. (B) The ECR111-BE-
MZ construct drives expression in the brain (arrowhead) and the somitic ECR111
domain. (C) Mutation of BS-1, BS-2 and BS-3 binding sites (construct ECR111[m123]-
BE-MZ) or (D) the single mutation of BS-1, abolish ECR111-driven expression at
10.5 dpc, but not that driven by the brain element (BE) used as a transgenesis
expression control (arrowheads in C and D).the BE (Fig. 4D; n=4). We found some variation in the levels of brain
expression, which is normal in transient transgenic embryos, but
ECR111-BE-MZ embryos that display very low levels of expression in
the brain were always associated with somitic expression, while
embryos carrying ECR111[m123]-BE-MZ or ECR111[m1]-BE-MZ
never show somitic expression, even if high levels are detected in
the brain. This shows that the M-CAT binding site is necessary for the
function of the ECR111 enhancer.
TEAD transcription factor family members bind to ECR111 in vivo
We analysed the speciﬁcity of the different TEAD antibodies by
western blot of in vitro translated proteins. TEAD-1 Ab (Aviva) is able
to bind weakly to TEAD1, TEAD3 and TEAD4 (data not shown); TEAD-
3 (Aviva) is able to recognise TEAD-1 and TEAD-3; TEAD-4 Ab (Aviva)
recognised TEAD-1, TEAD-3 and TEAD-4; TEAD-2 Ab (Santa Cruz),
TEAD-1 (BD Biosciences) and TEAD-4 (Santa Cruz) are highly speciﬁc
for their respective TEAD factors (Fig. S5). We then performed whole-
mount immunohistochemistry using the different antibodies against
the TEAD family of transcription factors to determine where in the
embryo the TEAD proteins are localised. The speciﬁc TEAD-2 Ab
(Santa Cruz) did not show ﬂuorescence in 10.0 dpc embryos, while
TEAD-3 Ab (Aviva) generates very faint immunoﬂuorescence in all
somites (data not shown). In contrast, TEAD-1 and TEAD-4 antibodies
(which recognise TEAD-1, 3 and 4) show clear protein localisation in
the heart and the somites (Figs. 5A–D). Immunohistochemistry on
sections of 10.5 dpc embryos shows that TEAD proteins mainly
localise to the myotome, with isolated cells present in the dermo-
myotome (Figs. 5E and F). Interestingly the localisation of the protein
Fig. 5. TEAD proteins localise to the myotome and the dermomyotome. Whole-mount immunohistochemistry with anti-TEAD1 (Aviva) (A and B) and anti-TEAD4 (Aviva) (C and D)
shows that TEAD proteins in the 10.0 dpc embryo localise to the developing heart and the somites, where staining is stronger in caudal and rostral regions. Immunohistochemistry on
sections from 10.5 dpc embryos with anti-TEAD1 (Aviva) (E–G), anti-TEAD1 (BD Biosciences) (H and I) and anti-TEAD4 (Santa Cruz) (J−L) shows that these TEAD proteins in the
somite are preferentially localised to the myotome in interlimb regions, although some dermomyotomal cells at this level are also positive (F, arrowheads). At tail somite levels
TEAD-4 seems to localise to the dermomyotome (L). (E, H, and J) are saggital sections at interlimb levels; (G and K) are transverse sections at interlimb levels; (L) is a transverse
section at tail somite level. White boxes in A, C, E and H indicate the close up regions shown as B, D, F and I. The numbers in brackets refer to the members of the TEAD family
recognised by the named antibody (see the text for information on the speciﬁcity of the TEAD antibodies).
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observed (Fig. 5E and F). Using the speciﬁc TEAD-1 (BD Biosciences)
antibody on sections shows that TEAD-1 in the somites is localised to
nuclei from myotome and dermomyotome cells, mainly present at
caudal regions (Figs. 5G–I). The speciﬁc TEAD-4 antibody (Santa Cruz)
shows the presence of TEAD-4 throughout the myotome of somites atFig. 6. The ECR111 enhancer is bound in vivo by members of the TEAD family of
transcription factors. ChIP analyses of (A) the ECR111 and (B) exon 1 regions show that
all TEAD antibodies used are able to immunoprecipitate the ECR111 enhancer. See the
text for information on the speciﬁcity of the TEAD antibodies. Input: sonicated
chromatin prior to immunoprecipitation; H2O: no chromatin added to the reaction;
+ve: total mouse genomic DNA; Ladder: 100 bp ladder (New England Biolabs).interlimb levels. In this case, staining is clearly observed in the
cytoplasm of myotubes (Figs. 5I and J). Interestingly, transverse
sections at interlimb level show that TEAD-4 is predominantly
localised to the myotome (Fig. 5K), while in tail somites expression
is restricted to the dermomyotome (Fig. 5L).
We then performed ChIP assays on chromatin isolated from
10.5 dpcmouse embryo trunks to determine if a member of the TEAD
family was binding to this enhancer in vivo. All TEAD-family
antibodies were able to recognise proteins bound to the ECR111
region in vivo (Fig. 6A), while none were able to immunoprecipitate
the DNA control region from exon1 of Myf5 (Fig. 6B). ChIP
experiments carried out with the more speciﬁc TEAD1 and TEAD4
antibodies failed to produce consistent results. As the antibodies that
consistently immunoprecipitate ECR111 recognise more than one
member of the family, we cannot determine at this stage exactly
which TEAD members are binding in vivo to the enhancer, but
combination of the western blot and ChIP data shows that: i) TEAD-2
is bound in vivo to the enhancer and ii) another TEAD member must
also be binding to the enhancer.
Discussion
We have previously shown that the transcriptional regulation of
the Mrf4/Myf5 locus depends on a series of enhancers that drive
highly speciﬁc temporal and anatomical aspects of the expression
of the two genes (Carvajal et al., 2001). The data clearly showed the
existence of at least two classes of elements: enhancers that require
the input of other enhancers in order to drive the correct expression
pattern, and enhancers that are able to drive a particular aspect of
the expression in isolation. ECR111 belongs to the latter group and
constitutes the most evolutionarily conserved sequence within the
locus. The results show that in isolation ECR111 controls a very
speciﬁc aspect of the somitic expression of Myf5, the same aspect
that is lost from the full expression pattern when the enhancer is
378 R. Ribas et al. / Developmental Biology 355 (2011) 372–380deleted from the locus, and strikingly it unveils a further
subdivision within the dermomyotomal lip domains. Finally, we
show by EMSA, ChIP and transgenic analyses that a highly
conserved TEAD binding site is essential for enhancer function
and that members of the TEAD family of transcription factors are
bound in vivo to the enhancer.
The ECR111 enhancer controls ventro-caudal and ventro-rostral Myf5
expression
We have previously shown that the−140 kb to−88 kb interval
is required for the ventral somitic expression of Myf5 and Mrf4
(Carvajal et al., 2001). While in most skeletal muscle progenitors,
Myf5 expression precedes that ofMrf4, in the somitic bud (the most
ventral aspect of the thoracic somites), the onset ofMyf5 expression
coincides with or closely follows that of Mrf4 (Summerbell et al.,
2002). Because of this coincidence in time and space, we have
previously hypothesised that a single enhancer may be responsible
for the activation of both genes in the ventral somitic compartment
(Carvajal et al., 2001), and we embarked on the characterisation of
enhancers within this 52 kb interval. Comparative sequence
analyses revealed the presence of at least four highly conserved
sequences within the interval, one of which (ECR111) is conserved
in all vertebrates, conservation that is higher than that of the coding
exons of Mrf4, Myf5 or the Ptprq gene, located immediately
upstream and harbouring ECR111 in one of its introns. Transgenic
animals carrying the ECR111-MZ construct express the reporter
gene in the ventral half of the myotome and the ventral quarter of
the dermomyotome of thoracic and cervical somites but not in the
somitic bud, indicating that another enhancer must drive this
aspect of the pattern. Furthermore, deletion of ECR111 from
B195APZ (construct B195APZΔ111) conﬁrms this ﬁnding as expres-
sion in the somitic bud is not affected and the only missing aspect of
the expression coincides with that driven by the enhancer in
isolation. Therefore, ECR111 belongs to the class of Mrf4/Myf5
"modular enhancers" the function of which does not need
additional input from other elements in the locus, placing it in
the same class as the EEE element (Teboul et al., 2002), the brain
element (Daubas et al., 2009) and the limb element (Hadchouel et
al., 2003). While this is true for the thoracic somitic pattern, it is
different in the tail somites where the enhancer in isolation is not
able to drive ventral expression, nor is the construct B195APZΔ111,
from which the enhancer has been deleted. The formation of tail
somites is different from that of thoracic and cervical somites. In the
mouse, the onset of tail somite formation occurs around 10.0 dpc
(Wilson and Beddington, 1996) and ends around 13.5 dpc, when
the total number of tail somites is reached (Tam, 1981). It has been
shown that signals emanating from the ventral ectodermal ridge
(Bmp2 and Fgf17), through the control of Wnt3a levels, are
essential for somitogenesis and tail elongation (Goldman et al.,
2000). Mice carrying the spontaneous mouse mutation vestigial tail
(a hypomorphic Wnt3a mutation) or lacking Wnt3a (Greco et al.,
1996) show reduced length or absent tail, respectively, while
anterior somitogenesis is unaffected; it has also been shown that
cervical and thoracic somites but not tail somites require cyclic
lunatic fringe expression (Shiﬂey et al., 2008; Stauber et al., 2009).
Therefore the signalling requirements for tail somite formation are
different from those of thoracic and cervical somite formation,
while the basic process of somitogenesis is probably shared
(reviewed in Pourquié, 2001). Our data indicate that the activation
requirements for tail and thoracic somitic ventral Myf5 expression
are also different, as ECR111 is necessary but not sufﬁcient to drive
this aspect of the tail pattern, indicating that differences in somite
formation may be reﬂected in the signalling requirements for
myogenesis in the tail as compared to the thoracic and cervical
somites.A TEAD binding site is essential for expression of Myf5 in the ventral
domain of caudal and rostral somitic edges
EMSA analyses showed several putative binding sites within
ECR111 and by using competition analyses with overlapping and
mutated oligonucleotides we reﬁned the location of these sites. While
binding-site prediction software is generally unreliable, due to the
natural variation of these sequences and the very limited availability
of fully characterised sites, our supershift analyses show that one of
the sites identiﬁed by EMSA and predicted as a canonical M-CAT
binding site, is bound in our in vitro assay by members of the TEAD
family of transcription factors. Mutation analyses carried out in
transgenic animals show that the TEAD binding site BS-6 is not
required for enhancer function (construct ECR111[m456]-MZ), while
embryos carrying the double enhancer construct ECR111[m1]-BE-MZ,
in which the TEAD BS-1 site has been mutated to abolish binding,
express the reporter gene in the brain, which acts as positive control
but not in the somitic domains controlled by ECR111. This shows that
the TEAD BS-1 site is absolutely required for ECR111 enhancer
function at 10.5 dpc. Nevertheless, a 200 bp sub-fragment of ECR111
carrying this binding site and the immediately downstream BS-2 and
BS-3 sites, was not able to drive transgene expression (Ribas and
Carvajal, unpublished observations). As the construct in which the
remaining sites identiﬁed by EMSA were mutated (ECR111[m456]-
MZ) was able to drive the entire ECR111 pattern, this suggests that
another site(s) not identiﬁed in our EMSA assay may also be required.
Although it is known that in some cases TEAD proteins may bind in
isolation, it has also been shown that their activity often depends on
the binding of other factors or co-factors such as Srf, Mef2, vestigial-
related proteins, bHLH proteins, TAZ (transcriptional co-activator
with PDZ-binding motif), or YAP (Cao et al., 2008; Farrance and
Ordahl, 1996; Gupta et al., 1997; Gupta et al., 2001; Larkin et al., 1996;
Lian et al., 2010; Maeda et al., 2002a; Maeda et al., 2002b; Mahoney et
al., 2005; Ota and Sasaki, 2008; Sawada et al., 2008; Zhao et al., 2008).
It is possible to speculate that a second transcription factor, that forms
a complex with the TEAD protein, is acting through the binding site(s)
present within oligo#25, as these are supershifted by increasing
concentrations of anti-TEAD1 antibody. It is also possible that the
second TEAD binding site at this location is active, but with a higher
afﬁnity for the TEAD protein than the chicken troponin-T consensus
sequence, although the partial competition by mutated oligo#25 will
argue against this possibility.
By using chromatin immunoprecipitation (ChIP) assays we have
also shown that members of the TEAD family of transcription factors
bind ECR111 in vivo, and the obvious interpretation is that this
binding occurs through the TEAD BS-1 binding site, which is 100%
conserved throughout vertebrate evolution, while the TEAD BS-6
binding site shows some sequence variation even among mammals.
Our ChIP analyses are limited by the speciﬁcity of the antibodies used
in the assay, and thus while we can show that one of the members
binding in vivo to the enhancer is TEAD2, we cannot at this point
distinguish between TEAD1 and TEAD3, one of which is also binding
to the enhancer as the TEAD3 antibody, which we show recognises
both TEAD1 and TEAD3, also immunoprecipitated the ECR111
sequence. Finally, we cannot be certain of the binding of TEAD4, as
the antibody used also recognises TEAD1 and TEAD3, and the more
speciﬁc anti-TEAD1 and anti-TEAD4 antibodies fail to generate
consistent data on ChIP analyses.
Zebraﬁsh contain at least three TEAD homologues, TEAD1 and two
TEAD3s, TEAD3a and TEAD3b (Mann et al., 2007). Interestingly, in the
zebraﬁsh embryo TEAD3a is initially expressed in adaxial cells but as
the differentiation of fast muscle starts at somite stage 18, TEAD3a
expression is detected throughout the somite, particularly strong at
the posterior ventral somitic domain, and by the end of somitogenesis
is restricted to the somite borders. Although some of the antibodies
that gave a positive immunohistochemistry signal in our whole-
379R. Ribas et al. / Developmental Biology 355 (2011) 372–380mount experiments recognise more than one member of the TEAD
family in Western blots, it is interesting to note the overlap in the
location of the TEAD proteins, mainly to myotome and dermomyo-
tomal edges at 10.0 dpc, although at later stages, unlike the zebraﬁsh
TEAD3a, mouse TEAD proteins are detected throughout the myotome.
Heterogeneity of signals in the dermomyotomal lips
It has been shown that the formation of the myotome in
vertebrates is an ordered process in which a ﬁrst wave of pioneer
cells colonise themyotome from the dermomyotomal dorsomedial lip
(DML) (Cinnamon et al., 1999; Denetclaw et al., 2001; Gros et al.,
2004; Kahane et al., 1998; Ordahl et al., 2001; Venters and Ordahl,
2002), and the expansion of the myotome at early stages is driven
only by myocytes delaminating from this source. Further growth of
the myotome is accomplished by the addition of myocytes from the
four lips of the dermomyotome so that the ﬁnal myotome is
compartmentalised in ﬁve regions depending on the source of
progenitor cells (Gros et al., 2004). Our data show that this
subdivision probably precedes myotome formation, as the dermo-
myotomal lips are already subdivided before colonisation of the
myotome. In agreement with this, we have previously shown that
expression ofMyf5 in the DML is driven by the EEE enhancer element
(Teboul et al., 2002), while precursors in the ventro-caudal and
ventro-rostral lips are subject to different environmental signals
acting through ECR111. In addition, we show that the expression of
Myf5 in the somitic bud is driven by a yet uncharacterised enhancer in
the −140 kb to −88 kb interval (Carvajal et al., 2001), which is
distinct from ECR111 (this work). Enhancer elements driving
expression ofMyf5 in the dorso-caudal and dorso-rostral dermomyo-
tomal lips have not been identiﬁed at this stage, although constructs
#1 and #2 from Summerbell et al. (2000) show clearMyf5 expression
in the dorso-caudal somitic domain, indicating that this unchar-
acterised enhancer is located close to the coding sequence of Myf5.
The function of TEAD proteins in early myogenesis
TEAD proteins have been shown to be direct targets of the Hippo
signalling pathway mediating YAP-activity through direct binding to
this co-activator and modulating YAP-induced epithelial to mesenchy-
mal transitions (Zhao et al., 2008) and progenitor cell proliferation and
survival (Cao et al., 2008; Lian et al., 2010; Ota and Sasaki, 2008; Sawada
et al., 2008). This latter function is a highly conserved pathway as
overexpression of Yorkie (the YAP homolog) in Drosophila, which is also
downstream of the Hippo pathway, leads to increased cell proliferation
and survival (Huang et al., 2005; Zhang et al., 2008). Furthermore, TEAD
proteins have also been implicated in cell growth and epithelial to
mesenchymal transition through the interaction with the TAZ co-
activator (Zhang et al., 2009) and in the development of neural crest
derivatives through the direct activation of Pax3 (Milewski et al., 2004).
Very recently it has been shown that in the C2C12 skeletal muscle
cell line activated YAP, which is unable to exit the nucleus, prevents
myotube differentiation (Watt et al., 2010). Furthermore, the authors
have also shown that activated YAP downregulates MyoD and Mef2,
which are essential for cell cycle exit and differentiation, and induces
Myf5 expression, which has been shown to promote myoblast
proliferation (Ishibashi et al., 2005). Therefore YAP function in
C2C12, as in the neural tube, promotes cell proliferation and
maintenance of the undifferentiated phenotype. It is therefore
possible that the function of the TEAD family in the caudal and rostral
lips of the dermomyotome through the ECR111 enhancer is to activate
Myf5 expression in order to allow for the proliferation of second wave
progenitor myocytes, promote the growth of the ventral myotome
and contribute to hypaxial muscle formation.
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